The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.
 
Anil A. Joy
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Shailendra Verma
Consulting or Advisory Role - Pfizer
 
Louise Provencher
Honoraria - Amgen; Novartis; Pfizer
Speakers' Bureau - Amgen
Research Funding - Amgen; AstraZeneca; Novartis; Pfizer; Roche
 
Kathy Puyana Theall
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Honoraria - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Dongrui (Ray) Lu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Florence Dequen
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Daniel Rayson
Consulting or Advisory Role - Ipsen; Pfizer; ROCHE Canada
Research Funding - IPSEN (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)